You can narrow down the results using the filters
-
An interventional study to evaluate the efficacy and safety of a donepezil transdermal patch compared to oral Aricept in Alzheimer's disease
Expand descriptionThe objective of this study is to evaluate the efficacy and safety of donepezil transdermal patch comparing to donepezil oral tablet (Aricept) in patients with mild to moderate Alzheimer’s disease.
-
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer (VAPOR-C): A Feasibility Study
Expand descriptionThis study aims to assess feasibility of conducting a randomised efficacy trial to compare two different methods of anaesthesia in patients undergoing major cancer surgery. Who is it for? You may be eligible to join this study if you are aged 18 years and over and are scheduled to undergo major cancer surgery expecting to last two or more hours. Study details Study participants will be allocated by chance to one of the two groups. Group 1 - Inhaled anaesthesia, Group 2 - Anaesthesia administered via a cannula into a vein in the arm. This study will inform conduct of a large efficacy trial which will aim to provide insight into the mechanisms by which anaesthetics potentially drive cancer progression with the ultimate goal of developing novel biomarkers and strategies to limit the impact of anaesthetics on cancer progression.
-
SImplification of Medications Prescribed to Long tErm care Residents (SIMPLER)
Expand descriptionComplex medication regimens are prevalent in residential aged care facilities (RACFs), can be burdensome for residents and are costly in terms of nursing time. The aim of this study is to investigate application of a structured process to simplify medication administration for residents of aged care facilities. We hypothesise this may reduce the total number of medication administration times and decrease time spent administering medications, and may improve clinical outcomes for residents. SImplification of Medications Prescribed to Long tErm care Residents (SIMPLER) is a non-blinded, matched-pair, cluster randomised controlled trial of a single multidisciplinary intervention to simplify medication regimens in RACFs. Research nurses will recruit English-speaking, permanent residents from 8 South Australian RACFs. Medications taken by residents in the intervention arm will be assessed once using a structured tool to identify opportunities to reduce medication regimen complexity (e.g. by administering all medications at the same time, or through the use of longer-acting or combination formulations). Residents in the comparison group will receive routine care. Participants will be followed for up to 3 years after study entry. The primary outcome will be the total number of charted medication administration times at four months after study entry. Secondary outcomes will include time spent administering medications, medication incidents, resident satisfaction, quality of life, falls, hospitalisation and mortality. Individual-level analyses that account for clustering will be undertaken to determine the impact of the intervention on the study outcomes. Study results will be disseminated via conference presentations and manuscripts submitted to peer reviewed journals.
-
IPINIVO - A Pharmacodynamics study of Nivolumab in Combination with Ipilimumab in Patients with Advanced or Metastatic Solid Tumours'
Expand descriptionThis study aims to evaluate the effects of Nivolumab in Combination with Ipilimumab on biochemical and physiologic functions in Subjects with Advanced or Metastatic Solid Tumors. Who is it for? You may be eligible to join this study if you are aged 18 years or above and have a histologically or cytologically confirmed, metastatic or locally advanced solid tumor for which no standard therapy exists or standard therapy has failed. Study details Approximately 21 eligible patients with advanced or metastatic solid tumors will be enrolled into two cohorts. In the first cohort, nine (9) subjects will receive 1mg/kg of ipilimumab every 6 weeks and Nivolumab 3mg/kg every 2 weeks until disease progression or discontinuation due to toxicity or a maximum of 12 weeks. The second cohort of twelve (12) subjects will receive 0.3mg/kg of ipilimumab every 6 weeks and Nivolumab 3mg/kg dosed every 2 weeks until disease progression or discontinuation due to toxicity or a maximum of 12 weeks. The investigators seek to identify/confirm circulating pharmacodynamic biomarkers that correlate with immune activation.
-
The effect of a physiotherapy exercise program with a self-management approach v's usual care on physical activity in people with mild-moderate Parkinson’s disease: A Randomised Controlled Trial
Expand descriptionDespite best medical intervention, people with Parkinson’s disease (PD) show a steady decline in physical functioning over time. Research shows that exercise is beneficial to improve and maintain physical function and physical activity in people with PD but a challenge is to maintain this over time. This project aims to assist people with PD to improve their physical activity levels and importantly maintain them, by trialling a new intervention of physiotherapy group sessions that combine exercise, self-monitoring with armbands and the self-management skills needed to improve their physical activity levels.
-
The effects of fish oil supplementation and resistance exercise on inflammation in healthy post-menopausal women
Expand descriptionThe aims of this project are to: a. investigate whether the serum composition of post-menopausal women can be altered with 4 weeks of fish oil supplementation and an acute bout of resistance exercise b. Can changes to inflammatory markers in serum alter the activity of muscle cells grown in-vitro Proposal research design: The study is a randomized cross-over design study with a 4 week washout period between groups: Fish Oil group. Participants will be required to ingest 4 fish oil capsules (6g/d containing 2.16g of EPA and 1.42g of DHA) PUFA daily for 4 weeks. This dose has been selected as it is the dosage range recommended by the Australian Heart Foundation for lowering plasma triglyceride concentrations in hypertriglyceridemic subjects and has therefore previously been shown to be physiologically relevant in human subjects. Placebo group. Participants will be required to ingest equivalent amounts of coconut oil (6g/d) for 4 weeks. Coconut oil has been selected as it has been used as a control in other studies involving fish oil. Resistance Exercise. The acute exercise intervention will consist of both upper and lower body exercises including: the leg press, leg extensions, the bench press and dumbbell side lateral raises. The duration of the exercise session, including adequate warm-ups, will be ~60 minutes.
-
Ultrasound-Guided regional Anaesthesia in Patients receiving Dressing Change After split-Skin grafting for Upper Limb burn Injuries: A Prospective Randomized Study
Expand descriptionREPAIR is a study investigating the role of regional anaesthesia (RA) for reducing pain experienced during dressing change for patients who require split skin grafting after suffering burn injuries to the upper limbs. There are approximately 50,000 burn related hospital admissions per annum in Australia at an economic cost of $230m. This patient cohort may experience neuropathic or nerve pain that is notoriously difficult to treat. This trial will compare current pain practice with the use of RA in patients who have suffered burns and require dressing changes on the ward post split-skin grafting procedures. This study aims to redefine the way clinicians treat burn pain, and to lay the ground work for further investigation into RA and optimization of care for patients with burn injuries. Aim: To assess the effectiveness of regional anaesthesia as an intervention for burn pain associated with change of dressings and removal of staples after split skin grafting procedures to the upper limbs. Objectives: 1. To compare and contrast the outcomes of two patient cohorts receiving removal of staples and dressing change after upper limb split skin grafting including: a. Control group receiving standard opioid intervention as per treating team. b. Cohort receiving a single dose nerve block to upper limb grafting site. Methods Prospective, randomised clinical trial. Following institutional ethical approval, 20 participants will be sourced from the Royal Brisbane and Women’s Hospital acute in-patient burns unit. Written, informed consent will be obtained before patients are enrolled in the study. Patients will only be enrolled if they meet the inclusion criteria, and consent to the study. This study population of 20 patients will be divided into two groups (10 patients in each) with a control and interventional group. Once informed consent is obtained, participants will be randomised into two groups using a random number generator and sealed envelopes.Group one (I) will receive standard opioid intervention as per their treating team. Group two (II) will receive will receive standard opioid intervention with the addition of an ultrasound guided single-shot axillary brachial plexus block using 0.375% ropivacaine of 20-30mls. All patients will be charted post-procedural pain relief and antiemetics as per their treating team, and the addition of regional blockade will not affect availability of pain relief in any way. All blocks will take place in the designated anaesthetic block room prior to dressing change procedure. Blocks will be placed by qualified and experienced anaesthetic fellows and consultants under direct ultrasound guidance, employing aseptic technique, and according to standard practice. Patients will be followed up by a study member and data will be collected pertaining to numeric pain scores and opioid requirements daily for 7 days post-procedure or until discharge from hospital if it occurs sooner.
-
Ultrasound-Guided Regional Anaesthesia In Patients Receiving Split-Skin Grafting For Various Burns With Donor Sites From The Upper Thigh: A Prospective Randomized Study
Expand descriptionRELIEVE is a study investigating the role of regional anaesthesia (RA) for reducing pain for patients who require split skin grafting after suffering burn injuries. There are approximately 50,000 burn related hospital admissions per annum in Australia at an economic cost of $230m. This patient cohort may experience neuropathic or nerve pain that is notoriously difficult to treat. This trial will compare current pain practice with the use of RA in patients who have suffered burns and require split skin grafting. This study aims to redefine the way clinicians treat burn pain, and to lay the ground work for further investigation into RA and optimization of care for patients with burn injuries. Aim: To assess the effectiveness of regional anaesthesia as an intervention for treating pain resulting from anterior thigh split skin graft donor sites in patients undergoing burn injury treatment. Objectives: To compare and contrast the outcomes of two patient cohorts receiving split skin grafts for burn related injuries: a. Control group receiving standard intervention for harvest of donor site skin from the anterior thigh as per treating team. b. Cohort receiving a single dose fascia iliaca plane block (FIPB) (incorporating blockade of the femoral nerve and lateral femoral cutaneous nerve of the thigh). Methods Prospective, randomised clinical trial. Following institutional ethical approval, 20 participants will be sourced from the Royal Brisbane and Women’s Hospital acute in-patient burns unit. Written, informed consent will be obtained before patients are enrolled in the study. Patients will only be enrolled if they meet the inclusion criteria, and consent to the study. This study population of 20 patients will be divided into two groups (10 patients in each) with a control and interventional group. Once informed consent is obtained, participants will be randomised into two groups using a random number generator and sealed envelopes. Group one (I) will receive standard opioid administration and surgeon local anaesthetic infiltration as per their treating team. Group two (II) will receive an ultrasound guided single-shot fascia iliaca plane block (FIPB) of 0.375% ropivacaine of 20-30mls to provide donor site analgesia on the day of surgery. All blocks will take place in the designated anaesthetic block room prior to general anaesthetic for split skin graft harvesting. Blocks will be placed by qualified and experienced anaesthetic fellows and consultants under direct ultrasound guidance, employing aseptic technique, and according to standard practice. Patients will be followed up by a study member and data will be collected pertaining to numeric pain scores and opioid requirements daily for 7 days post-procedure or until discharge from hospital if it occurs sooner.
-
Exploring changes in breast milk composition as markers of mastitis in mothers of preterm infants
Expand descriptionBackground: Mastitis is a common inflammatory complication of lactation that may progress to infection. The onset may be insidious or sudden, and it impacts maternal wellbeing through breast pain, fever and flu like symptoms. Mastitis may progress to abscess, and potentially impacts the health of the preterm infant through reduced milk production and possible transmission of infection. Mothers of hospitalised preterm infants are at increased risk of mastitis due to a number of predisposing factors including use of a breast pump, poor health of the mother and/or infant, and exposure to pathogens within the hospital environment. Early detection and treatment of mastitis is critical to limiting its severity, with microbiological culture of milk recommended for hospital acquired cases. While an elevated milk sodium:potassium (Na:K) ratio is considered a marker of mastitis there are currently no clinical tests to confirm its onset. Mothers of hospitalised infants are typically required to access community based medical care for suspected mastitis. This can be difficult as they are typically dependent on others for transport after a caesarean birth, and insidious symptoms can be overlooked. Point of care (POC) screening of breast milk for elevated Na:K may offer a clinical tool for early detection of mastitis and therefore timely management, thus minimising the impact on the mother and infant. Objectives: To determine whether milk Na:K >1.0 ratios measured at POC are associated with mastitis in mothers of preterm infants. To determine the incidence of mastitis in a sample of mothers who are expressing milk for their hospitalised preterm infants. To determine whether acute reductions in 24-hour milk production volumes are associated with markers of mastitis. Trial Plan: An observational study of 65 mothers of preterm infants will be carried out. Breast milk Na and K concentrations will be measured at POC and Na:K calculated every second day from day 2 to day 10, and then every 3rd day until infant discharge from the neonatal nurseries of the study hospital. In the event of suspected mastitis, Na and K monitoring will occur daily from onset to 48 hours post resolution of symptoms. Microbiological cultures of milk samples will be performed on day 8, day 13 and every 6 days until infant discharge, and at the onset of mastitis. Breast symptoms and milk production volumes will be recorded at each sampling time point. Incidence of mastitis and breastfeeding outcomes will be tracked to 8 weeks postnatal
-
Change in Australian adults’ eating habits from 1995 to 2011-13
Expand descriptionThis study used data from two nationally representative surveys, the 1995 National Nutrition Survey and the 2011-13 National Nutrition and Physical Activity Survey, conducted by the Australian Bureau of Statistics. The purpose of this study was to examine change in dietary intakes of energy, macronutrients, fiber, fruits and vegetables among Australian adults between 1995 and 2011-13, according to socioeconomic position (educational level, household income, neighbourhood disadvantage).